EyePoint Pharmaceuticals (EYPT) AI Stock Analysis

• Market Cap: $1.10B
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: -7.38%
• EPS Growth: -49.03%
• Country: US
• Employees: 165
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 83,431,950
• 10 Day Avg. Volume: 1,265,144
• 30 Day Avg. Volume: 1,636,030
• PEG Ratio: -0.16
• Price to Book (P/B): 4.37
• Price to Sales (P/S): 42.66
• P/FCF Ratio: -5.50
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: 32.60
• Enterprise Value/Gross Profit: 34.90
• Enterprise Value/Ebitda: -4.27
• 1Y Price Target: $36.60
• Price Target Upside: 176.64% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): -3.22
• Revenue Forecast (FY): $3.79M

• Rating: 48 Neutral
• Price Target: $13.50 ▲(2.04% Upside)
• Action: Reiterated Date: 03/21/26
• Date: Action: Reiterated 03/21/26

The score is held down primarily by weak financial performance (declining revenue, widening losses, and heavy cash burn) and bearish technical signals. Offsetting these are a comparatively solid balance sheet/runway and a favorable earnings-call backdrop driven by Phase 3 progress and defined upcoming data catalysts, while valuation offers limited support due to negative earnings and no dividend.

Positive Factors

Phase 3 Progress

Advancing DuraVu into global Phase 3 for wet AMD and initiating two pivotal DME trials establishes a clear regulatory and clinical path. Durable late-stage progress reduces binary early-stage risk, enables regulatory filings and commercial planning, and materially raises the potential for multi-indication revenue streams if trials succeed.

Differentiated MOA & Efficacy

A multi-mechanistic profile (VEGF/PDGF/IL-6 via JAK1) with Phase 2 signals of earlier and durable vision benefit versus aflibercept supports a sustainable competitive advantage. If replicated in Phase 3, reduced treatment burden and stronger efficacy could drive durable market share, payer interest, and physician adoption over time.

Near-term Capital Runway

A meaningful cash position after a $173M follow-on provides funding continuity to complete pivotal wet AMD and DME programs and prepare NDA submission. This runway materially lowers near-term financing risk, enabling focused execution on trials, CMC readiness and prelaunch commercial activities without immediate dilutive pressure.

Negative Factors

High Cash Burn

Sustained, large negative operating and free cash flow signals structural funding dependency: ongoing R&D and OpEx outpaces revenue generation. Over multiple quarters this reduces financial flexibility, increases the likelihood of future financings if milestones slip, and elevates execution and dilution risk for a capital-intensive biotech.

Revenue Decline

Meaningful year-over-year revenue contraction weakens the company’s ability to offset escalating development costs. Declining commercial receipts (partly deferred revenue effects) reduce operating leverage, make funding more reliant on capital markets, and limit internal reinvestment capacity for commercialization and lifecycle activities.

Rising OpEx & Widening Losses

Material increases in operating expenses tied to Phase 3 ramp are driving sharply wider losses. Persistent negative margins reduce return on invested capital and make long-term sustainability contingent on trial success and eventual commercial adoption; delays or setbacks would exacerbate funding and execution pressures.

EyePoint Pharmaceuticals Business Overview & Revenue Model

Company Description

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

EyePoint makes money primarily by commercializing ophthalmic products and by generating revenue from collaborations related to its drug delivery and product development activities. Product revenue is driven by sales of its marketed ophthalmic therapy(s) to customers in the eye-care/retina treatment channel. The company also earns collaboration-related revenue when it enters into agreements with other pharmaceutical or biotechnology companies—typically through payments such as upfront fees, research or development funding, milestone payments tied to technical or regulatory progress, and/or royalties or profit-sharing on partnered products if they reach commercialization. Any additional revenue may come from licensing its technology or intellectual property to partners, where payments can similarly include upfront consideration, milestones, and ongoing royalties. null

EyePoint Pharmaceuticals Financial Statement Overview

Summary

Overall fundamentals are weak: 2025 revenue fell sharply and losses widened materially, while operating and free cash flow were deeply negative (heavy cash burn). The main offset is a relatively solid biotech balance sheet with low leverage and meaningful equity/cash to support ongoing development, but funding/execution risk remains elevated until burn moderates.

Income Statement

Profitability remains weak: the company is generating consistently negative earnings, and losses expanded sharply in 2025 (net loss of ~$232M vs. ~$131M in 2024). Revenue also declined meaningfully in 2025 (down ~26% year over year) after being roughly flat to modestly positive in prior years. A key positive is very strong gross profitability (gross margin ~93% in 2025), but operating costs continue to overwhelm gross profit, driving very large negative operating and net margins.

Balance Sheet

The balance sheet looks relatively solid for a biotech: leverage is low, with debt-to-equity around ~0.07 in 2025 and total debt of ~$21M against equity of ~$306M. Equity is substantial, which provides financial flexibility, but persistent losses are translating into weak returns on equity (negative in every year shown), and assets declined in 2025 versus 2024, signaling some balance-sheet burn over time.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow were deeply negative in 2025 (about -$240M and -$243M, respectively) and deteriorated materially versus 2024. Free cash flow has been negative in nearly all years shown (only 2023 was close, with slightly negative free cash flow), implying ongoing external funding needs. A modest positive is that cash burn is broadly consistent with reported losses (free cash flow roughly in line with net loss in 2024–2025), but the magnitude of the burn is the key risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	31.37M	43.27M	46.02M	41.40M	36.94M
Gross Profit	29.30M	39.56M	41.39M	33.08M	28.76M
EBITDA	-243.43M	-129.23M	-69.00M	-96.62M	-50.15M
Net Income	-231.96M	-130.87M	-70.80M	-102.25M	-58.42M
Balance Sheet
Total Assets	364.00M	418.46M	355.18M	180.36M	263.37M
Cash, Cash Equivalents and Short-Term Investments	306.09M	370.91M	331.05M	144.56M	211.56M
Total Debt	20.77M	21.86M	4.91M	46.35M	39.20M
Total Liabilities	57.88M	81.96M	88.86M	83.99M	78.99M
Stockholders Equity	306.11M	336.50M	266.32M	96.37M	184.38M
Cash Flow
Free Cash Flow	-243.39M	-130.28M	-1.61M	-67.16M	-50.25M
Operating Cash Flow	-240.11M	-126.23M	1.88M	-65.00M	-50.10M
Investing Cash Flow	68.58M	-219.35M	-3.31M	-17.27M	-33.12M
Financing Cash Flow	173.65M	164.02M	187.07M	-690.00K	216.90M

EyePoint Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Negative. The current price of 13.23 is below the 20-day moving average (MA) of 15.74, below the 50-day MA of 15.09, and above the 200-day MA of 13.15, indicating a neutral trend. The MACD of -0.55 indicates Positive momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 20.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EYPT.

EyePoint Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	61 Neutral	$1.98B	-273.00	-2.05%	―	1128.17%	―
PHAR	57 Neutral	$1.11B	440.65	0.83%	―	26.54%	―
TNGX	55 Neutral	$2.77B	-10.13	-50.30%	―	53.28%	21.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
URGN	49 Neutral	$857.78M	-7.34	170.21%	―	8.00%	-10.15%
EYPT	48 Neutral	$1.10B	-5.61	-88.31%	―	-7.38%	-49.03%
MGTX	47 Neutral	$579.53M	-3.30	-1065.47%	―	96.83%	-61.92%

EyePoint Pharmaceuticals Corporate Events

EyePoint Sues Ocular Therapeutix Over Alleged Defamation

On March 20, 2026, EyePoint, Inc. filed a lawsuit in Middlesex County Superior Court in Massachusetts against Ocular Therapeutix, Inc., alleging the rival disseminated false or misleading statements about EyePoint and the clinical results of its lead retinal drug candidate, DURAVYU. The complaint claims defamation, commercial disparagement, violation of Massachusetts consumer protection law, and tortious interference with business relations, as EyePoint seeks injunctive relief to halt the statements, a public retraction, and monetary damages, underscoring the intensity of competitive and reputational stakes in the ophthalmic pharmaceuticals sector.

The most recent analyst rating on (EYPT) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Starts Global Phase 3 Trials for DURAVYU

On March 2, 2026, EyePoint announced that the first patients have been dosed in its global Phase 3 COMO and CAPRI clinical trials evaluating DURAVYU for diabetic macular edema, signaling the start of pivotal late-stage testing in a major retinal indication. These randomized, aflibercept-controlled non-inferiority studies, each targeting about 240 patients and using six‑month redosing, are designed to leverage positive Phase 2 VERONA data and prior regulatory alignment in the U.S. and Europe to demonstrate that DURAVYU can match standard-of-care vision outcomes while reducing treatment burden.

The launch of these DME trials, alongside an already fully enrolled Phase 3 program in wet AMD, underscores EyePoint’s bid to establish DURAVYU as a first- and best-in-class sustained-release tyrosine kinase inhibitor in the two largest retinal disease markets. Successful results, with topline DME data expected in the second half of 2027 and wet AMD data anticipated beginning in mid-2026, could materially strengthen the company’s competitive position in ophthalmology, offering patients a longer-acting, multi-mechanism alternative to existing anti-VEGF therapies and potentially reshaping treatment paradigms for vision‑threatening diabetic eye disease.

The most recent analyst rating on (EYPT) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.